Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2014 event was held May 30-June 3. The next ASCO Annual Meeting will be held May 29-June 2, 2015, in Chicago. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
In a large, 20-year study, researchers found that men with a high level of fitness at middle age have a lower risk of developing and dying from lung and colorectal cancers. They also found that better fitness lowers the risk of dying of prostate cancer.
Patients with stage III non-small cell lung cancer (NSCLC) who participated in a recent study lived longer and had fewer side effects when they received the standard dose of radiation therapy and not the high-dose radiation therapy. Stage III NSCLC is usually difficult or impossible to remove with surgery. Radiation therapy is used to slow the growth and spread of the cancer to lengthen patients’ lives. The standard dose for radiation therapy is 60 Gray (Gy), a measurement of how much radiation is absorbed by the body, although many doctors use higher doses in the hope of better controlling the cancer’s growth.
New findings from a retrospective study suggest that targeted anti-HER2 therapy may slow disease progression in patients with advanced lung cancer who carry a specific alteration in HER2—a protein that controls cancer growth and spread, found on some cancer cells, such as breast, ovarian, and lung cancer cells.
New findings from a clinical trial in patients with colorectal cancer and inoperable metastases in the liver (cancer that has spread from the colon or rectum to the liver) suggest that combination treatment with standard therapy and targeted drug cetuximab (Erbitux) caused significant shrinkage of metastases, making successful surgery feasible.
Analysis of data collected in a large, population-based study in Shanghai, China, showed women who consumed higher amounts of soy food in the years leading up to their diagnosis of lung cancer lived longer. These results offer the first scientific evidence that consuming soy food before cancer diagnosis may be associated with significantly improved survival in patients with lung cancer.
New findings from a prospective clinical trial in children with non-hereditary retinoblastoma affecting only one eye (unilateral retinoblastoma) will help doctors identify patients who should not receive chemotherapy after surgical removal of the diseased eye.
A recent analysis of information from the Surveillance Epidemiology and End Results (SEER) database showed that patients who had surgery to remove small kidney tumors (tumors that are less than 1.5 inches across) have the same risk of dying of kidney cancer over a five-year period as those who received surveillance instead. Surveillance of kidney cancer involves using imaging tests, such as magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT or CAT) scans to watch for signs that the cancer is growing or worsening.
In a new study, researchers found that patients with high-risk prostate cancer who received hormone therapy for 18 months lived as long as patients who received hormone therapy for 36 months. Androgens (male sex hormones), such as testosterone, help prostate cancer grow. Hormone therapy, also called androgen blockade therapy or androgen deprivation therapy, slows the growth of prostate cancer by lowering the levels of androgens or blocking the androgens from getting to the prostate cancer cell. It is a standard treatment for prostate cancer. However, long-term hormone therapy causes many side effects, such as hot flashes, loss of libido (sex drive), erectile dysfunction, weight gain, loss of bone density and muscle mass, and depression that worsen during the length of treatment. With this study, researchers hoped that a shorter course of hormone therapy would help treat the cancer equally well while reducing the side effects.
A recent analysis showed that early-stage, but aggressive (grows and spreads quickly) prostate cancer is more likely to be detected in black men and men older than 75. Generally, the percentage of men with this type of prostate cancer is very small (about 1 man out of 8,000 men develops this type of prostate cancer). Because this stage of prostate cancer causes no symptoms and cannot be felt during a physical exam or seen on imaging tests, it is only detected through prostate specific antigen (PSA) testing. PSA is a substance in the blood that is primarily made by the prostate gland. It can be found in higher-than-normal levels in men with various prostate conditions, including prostate cancer, benign (noncancerous) prostatic hyperplasia (BPH, an enlarged prostate), and inflammation or infection of the prostate.
An early ongoing study suggests that looking at gene expression (which genes within each tumor are turned on or off) may help doctors predict how well chemotherapy will work and monitor how well chemotherapy is treating the cancer. Some genes within pancreatic tumors are similar between patients and some are different. These differences affect how well cancer drugs work for each patient.